Literature DB >> 1961391

Treatment of neoplastic spinal cord compression: results of a prospective study.

N Sundaresan1, G V Digiacinto, J E Hughes, M Cafferty, A Vallejo.   

Abstract

Currently, external radiation and steroid therapy are used in most patients with neoplastic spinal cord compression. Surgery is generally used to treat those who do not respond to radiation therapy. To determine the role of de novo surgery in patients with spinal metastases, a prospective study was undertaken. Over a 4 1/2-year period, the cases of 54 patients with radiologically documented spinal metastases were studied. The sites of tumor origin included soft tissue sarcoma (8 patients), kidney (6 patients), lung (5 patients), breast (5 patients), spine (6 patients), unknown primary site (6 patients), and others (18 patients). Sites of compression included the cervical spine segments in 15 patients, thoracic segments in 23, lumbar in 14, and sacral in 2. Before surgery, 24 patients (44%) were nonambulatory. Three surgical approaches were used: anterior vertebral body resection in 45 patients, laminectomy in 7, and lateral osteotomy in 2. After surgery, 37 patients received external radiation therapy. All patients improved (became ambulatory) after surgery, with 23 of 25 patients surviving at 2 years continuing to be ambulatory. The 30-day mortality rate was 6% (three patients); eight patients (15%) sustained various surgical complications. These results are superior to those reported after external radiation therapy and steroids alone, and they support the concept that de novo surgery be considered in selected patients with spinal metastases.

Entities:  

Mesh:

Year:  1991        PMID: 1961391     DOI: 10.1097/00006123-199111000-00001

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  43 in total

1.  Clinical profile of long-term survivors of breast or thyroid cancer with metastatic spinal tumours.

Authors:  Y Kasai; E Kawakita; A Uchida
Journal:  Int Orthop       Date:  2006-04-26       Impact factor: 3.075

2.  A meta-analysis of surgery versus conventional radiotherapy for the treatment of metastatic spinal epidural disease.

Authors:  Paul Klimo; Clinton J Thompson; John R W Kestle; Meic H Schmidt
Journal:  Neuro Oncol       Date:  2005-01       Impact factor: 12.300

Review 3.  Surgical management of spinal mesenchymal tumors.

Authors:  Milan G Mody; Ganesh Rao; Laurence D Rhines
Journal:  Curr Oncol Rep       Date:  2006-07       Impact factor: 5.075

Review 4.  Review of metastatic spine tumour classification and indications for surgery: the consensus statement of the Global Spine Tumour Study Group.

Authors:  David Choi; A Crockard; C Bunger; J Harms; N Kawahara; C Mazel; R Melcher; K Tomita
Journal:  Eur Spine J       Date:  2009-12-29       Impact factor: 3.134

5.  Outcome of excisional surgeries for the patients with spinal metastases.

Authors:  Haomiao Li; Alessandro Gasbarrini; Michele Cappuccio; Silvia Terzi; Stefania Paderni; Loris Mirabile; Stefano Boriani
Journal:  Eur Spine J       Date:  2009-08-05       Impact factor: 3.134

Review 6.  The use of radiation in the management of spinal metastases.

Authors:  C M Faul; J C Flickinger
Journal:  J Neurooncol       Date:  1995       Impact factor: 4.130

Review 7.  Surgical indications and prognosis in spinal metastases.

Authors:  K Nanassis; C Alexiadou-Rudolf; J Rudolf; R A Frowein
Journal:  Neurosurg Rev       Date:  1997       Impact factor: 3.042

8.  Prognostic factors in anterior decompression for metastatic cord compression. An analysis of results.

Authors:  E Sucher; J Y Margulies; Y Floman; G C Robin
Journal:  Eur Spine J       Date:  1994       Impact factor: 3.134

Review 9.  Surgery for metastatic spinal disease.

Authors:  W C Welch; G B Jacobs
Journal:  J Neurooncol       Date:  1995       Impact factor: 4.130

Review 10.  Spinal cord compression in prostate cancer.

Authors:  J L Osborn; R H Getzenberg; D L Trump
Journal:  J Neurooncol       Date:  1995       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.